- Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies2022 | First Faculty of Medicine
- Evaluation of immunotherapy in treatment of advanced renal cell carcinoma2004 | Second Faculty of Medicine
- Interferon alpha in the treatment for advanced renal cell carcinoma2006 | Faculty of Medicine in Hradec Králové
- Integration of surgery and molecular tarteted therapy in advanced renal cell carcinoma2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma2015 | Publication without faculty affiliation
- Integration of surgery and molecular targeted therapy in advanced renal cell carcinoma2011 | Second Faculty of Medicine
- Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study2015 | First Faculty of Medicine
- 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation2013 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial2023 | First Faculty of Medicine
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma2017 | First Faculty of Medicine
- Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial2021 | First Faculty of Medicine
- Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Komentář ke studii (Axitinib v léčbě pokročilého renálního karcinomu: přehled účinnosti a bezpečnosti)2016 | First Faculty of Medicine
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study2023 | First Faculty of Medicine
- Komentář ke studii (Celkové přežití a prognostické faktory u pacientů s pokročilým karcinomem ledviny léčených 1. linií cílené léčby - analýza databáze SEER)2017 | First Faculty of Medicine
- Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Komentář ke studii2022 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. AGS-003-007Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: AGS-003-007Publication without faculty affiliation
- Cabozantinib in the treatment of RCC2018 | First Faculty of Medicine
- Sunitib in adjuvant treatment for renal cell carcinoma2017 | Publication without faculty affiliation
- Renal cell carcinoma 20152015 | First Faculty of Medicine
- Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b(5) Activity2020 | Faculty of Science
- Inferior vena cava reconstruction in a patient with locally advanced and recurrent renal cancer2022 | First Faculty of Medicine, Second Faculty of Medicine
- Transabdominal two-cavity approach for radical nephrectomy combined with inferior vena cava thrombectomy for malignant thrombus caused by renal cell carcinoma: A case series2018 | First Faculty of Medicine, Faculty of Physical Education and Sport